LL-37 is a peptide studied in inflammation and wound healing. The existence of clinical research does not mean every LL-37 formulation has been tested or produces the same outcomes.
What the research shows
The 2021 phase 2b HEAL LL-37 trial evaluated a topical preparation alongside compression therapy in 148 patients with difficult venous leg ulcers. The full-population analysis found no significant healing improvement versus placebo; subgroup observations should not become broad efficacy claims. [1] [2]
Distinguishing substances and products
The trial's topical preparation and an LL-37 vial require separate evidence. A description such as antimicrobial peptide is not itself proof that a product treats infection.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Does the trial establish benefit for every wound?
No. It studied venous ulcers, and the overall efficacy analysis was not significantly better than placebo.
Can topical evidence validate another vial presentation?
Only matching formulation evidence can support that comparison.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.